Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers
Clinical trial NCT02803203 · COMPLETED
Trial details
- NCT number
- NCT02803203
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-29
- Primary completion
- 2022-03-01
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.